AAIC 2025 Abstract·25 DecTML‐6, A Novel Oral Multi‐Target Drug: Design of a Global Phase II Trial Investigating Safety, Tolerability, and Efficacy with Integration of Blood Biomarkers in Early Alzheimer’s Disease.InterventionsPaper